Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATOS Atossa Genetics	$0.87 -2.5%	$0.87	$0.55 ▼ $1.66	$115.17M	0.9	750,129 shs	948,862 shs
GNLX Genelux	$3.40 +11.1%	$2.82	$1.60 ▼ $5.89	$115.55M	-0.34	173,416 shs	193,889 shs
KRRO Korro Bio	$13.83 +5.1%	$13.42	$10.29 ▼ $98.00	$123.58M	2.43	108,551 shs	143,739 shs
SNYR Synergy CHC	$3.63 +5.8%	$2.45	$0.36 ▼ $10.00	$31.54M	N/A	90,278 shs	81,983 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATOS Atossa Genetics	-2.48%	-2.07%	+7.28%	+39.54%	-37.45%
GNLX Genelux	+11.11%	-1.16%	+12.58%	+29.28%	+38.78%
KRRO Korro Bio	+5.09%	+1.77%	+9.76%	-0.50%	-71.40%
SNYR Synergy CHC	+5.83%	+13.44%	+67.28%	+45.78%	+1,810.53%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATOS Atossa Genetics	3.189 of 5 stars	3.7	4.0	3.8	1.7	0.0
GNLX Genelux	1.2659 of 5 stars	3.6	0.0	2.7	0.0	0.0
KRRO Korro Bio	1.5461 of 5 stars	3.6	1.0	1.6	0.0	0.6
SNYR Synergy CHC	3.8208 of 5 stars	3.8	0.0	2.7	3.3	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATOS Atossa Genetics	3.33	Buy	$6.17	609.22% Upside
GNLX Genelux	3.20	Buy	$17.75	422.06% Upside
KRRO Korro Bio	3.29	Buy	$102.43	640.63% Upside
SNYR Synergy CHC	3.50	Strong Buy	$10.00	175.48% Upside

Current Analyst Ratings Breakdown

Latest SNYR, GNLX, ATOS, and KRRO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/6/2025	ATOS Atossa Genetics	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.25 ➝ $7.50
6/5/2025	ATOS Atossa Genetics	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$4.00
5/13/2025	KRRO Korro Bio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00 ➝ $25.00
5/13/2025	KRRO Korro Bio	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$155.00 ➝ $90.00
5/8/2025	GNLX Genelux	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Speculative Buy ➝ Speculative Buy	$25.00 ➝ $23.00
5/8/2025	KRRO Korro Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$115.00 ➝ $100.00
4/29/2025	KRRO Korro Bio	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/28/2025	KRRO Korro Bio	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$74.00
4/21/2025	ATOS Atossa Genetics	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $7.25

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATOS Atossa Genetics	N/A	N/A	N/A	N/A	$0.57 per share	N/A
GNLX Genelux	$10K	12,838.40	N/A	N/A	$0.76 per share	4.47
KRRO Korro Bio	$2.27M	57.21	N/A	N/A	$17.12 per share	0.81
SNYR Synergy CHC	$34.83M	0.96	$0.28 per share	12.90	($1.91) per share	-1.90

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATOS Atossa Genetics	-$25.50M	-$0.21	N/A	N/A	N/A	N/A	-33.90%	-31.53%	8/11/2025 (Estimated)
GNLX Genelux	-$29.87M	-$0.88	N/A	N/A	N/A	N/A	-93.04%	-74.17%	8/13/2025 (Estimated)
KRRO Korro Bio	-$83.58M	-$9.44	N/A	N/A	N/A	N/A	-51.64%	-37.94%	8/12/2025 (Estimated)
SNYR Synergy CHC	$2.12M	N/A	0.00	6.15	N/A	N/A	-8.48%	12.75%	N/A

Latest SNYR, GNLX, ATOS, and KRRO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	N/A	GNLX Genelux	-$0.22	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	KRRO Korro Bio	-$2.54	N/A	N/A	N/A	$0.41 million	N/A
8/11/2025	Q2 2025	ATOS Atossa Genetics	-$0.06	N/A	N/A	N/A	N/A	N/A
5/15/2025	Q1 2025	SNYR Synergy CHC	$0.07	$0.10	+$0.03	$0.10	$9.03 million	$8.17 million
5/13/2025	Q1 2025	ATOS Atossa Genetics	-$0.06	-$0.05	+$0.01	-$0.05	N/A	N/A
5/8/2025	Q1 2025	GNLX Genelux	-$0.24	-$0.21	+$0.03	-$0.21	N/A	N/A
5/7/2025	Q1 2025	KRRO Korro Bio	-$2.60	-$2.49	+$0.11	-$2.49	$0.13 million	$2.55 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATOS Atossa Genetics	N/A	N/A	N/A	N/A	N/A
GNLX Genelux	N/A	N/A	N/A	N/A	N/A
KRRO Korro Bio	N/A	N/A	N/A	N/A	N/A
SNYR Synergy CHC	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATOS Atossa Genetics	N/A	12.67	12.67
GNLX Genelux	N/A	4.67	4.67
KRRO Korro Bio	N/A	9.41	9.41
SNYR Synergy CHC	N/A	1.91	1.62

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATOS Atossa Genetics	12.74%
GNLX Genelux	37.33%
KRRO Korro Bio	13.18%
SNYR Synergy CHC	N/A

Insider Ownership

Company	Insider Ownership
ATOS Atossa Genetics	7.60%
GNLX Genelux	9.30%
KRRO Korro Bio	4.60%
SNYR Synergy CHC	56.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATOS Atossa Genetics	8	129.17 million	119.35 million	Optionable
GNLX Genelux	10	37.76 million	34.25 million	Not Optionable
KRRO Korro Bio	70	9.39 million	8.96 million	No Data
SNYR Synergy CHC	40	9.19 million	3.99 million	N/A

SNYR, GNLX, ATOS, and KRRO Headlines

Recent News About These Companies

Synergy CHC Expands Retail Presence in North America

June 30, 2025 | tipranks.com

Synergy CHC Corp. (SNYR) Stock Price Today - WSJ

June 24, 2025 | wsj.com

Synergy CHC (NASDAQ: SNYR) Expands FOCUSfactor® to UAE & Turkey — Ignites Global Growth and New Revenue Streams

June 18, 2025 | finance.yahoo.com

Synergy CHC Corp. Expands International Licensing Deal with Gravity Pharma to Include Turkey, Securing $2 Million in Revenue

June 18, 2025 | quiverquant.comQ

Here is What You Need to Know Before Investing in Synergy CHC Corp. (SNYR)

June 18, 2025 | finance.yahoo.com

Here is What You Need to Know Before Investing in Synergy CHC Corp. (SNYR)

June 16, 2025 | insidermonkey.com

Synergy CHC Corp. (Uplisting) (NASDAQ:SNYR) CEO Jack Ross Buys 9,400 Shares

June 12, 2025 | insidertrades.com

New to The Street TV Spotlights Synergy CHC (NASDAQ:SNYR) as Former Coca-Cola Executive Joins to Drive FOCUSfactor(R) Energy Drink’s Global Expansion

June 11, 2025 | freep.comF

New to The Street TV Spotlights Synergy CHC (NASDAQ:SNYR) as Former Coca-Cola Executive Joins to Drive FOCUSfactor(R) Energy Drink's Global Expansion

June 10, 2025 | guardonline.comG

Synergy CHC Corp. Appoints Damian Marano as Vice President of Beverage to Accelerate Functional Beverage Expansion

June 10, 2025 | quiverquant.comQ

Synergy CHC (NASDAQ: SNYR) Taps Former Coca-Cola Executive to Help Drive FOCUSfactor Energy Drink Global Expansion

June 10, 2025 | globenewswire.com

Synergy CHC secures $20 million loan for growth and debt repayment

June 5, 2025 | investing.com

Synergy CHC Secures $20 Million Loan Agreement

June 4, 2025 | msn.com

Synergy CHC Announces New $20 Million Long-Term Credit Facility

June 4, 2025 | globenewswire.com

SNYR Synergy CHC Corp.

May 30, 2025 | seekingalpha.com

Synergy CHC Announces Appointment of Erik Shields as Vice President of Beverage

May 29, 2025 | finance.yahoo.com

Synergy CHC Corp. (Uplisting) (NASDAQ:SNYR) CEO Jack Ross Buys 5,000 Shares

May 22, 2025 | insidertrades.com

Analysts Offer Insights on Consumer Goods Companies: Wilmar International (OtherWLMIF) and Synergy CHC (SNYR)

May 21, 2025 | theglobeandmail.com

Synergy CHC Corp (SNYR) Q1 2025 Earnings Call Highlights: Navigating Revenue Challenges with ...

May 16, 2025 | uk.finance.yahoo.com

Synergy CHC Corp. Reports Strong Q1 2025 Earnings

May 15, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
2 Under the Radar Space & Defense Stocks With Huge Potential
By Leo Miller | July 1, 2025
View 2 Under the Radar Space & Defense Stocks With Huge Potential
3 Drone Stocks Take Flight on Hegesth's Bold Memo: Who and Why
By Leo Miller | July 16, 2025
View 3 Drone Stocks Take Flight on Hegesth's Bold Memo: Who and Why

SNYR, GNLX, ATOS, and KRRO Company Descriptions

Atossa Genetics NASDAQ:ATOS

$0.87 -0.02 (-2.48%)

Closing price 07/17/2025 04:00 PM Eastern

Extended Trading

$0.90 +0.03 (+3.51%)

As of 07/17/2025 07:21 PM Eastern

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

Genelux NASDAQ:GNLX

$3.40 +0.34 (+11.11%)

Closing price 07/17/2025 04:00 PM Eastern

Extended Trading

$3.20 -0.20 (-5.74%)

As of 07/17/2025 07:56 PM Eastern

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

Korro Bio NASDAQ:KRRO

$13.83 +0.67 (+5.09%)

Closing price 07/17/2025 04:00 PM Eastern

Extended Trading

$13.57 -0.26 (-1.88%)

As of 07/17/2025 06:11 PM Eastern

Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Synergy CHC NASDAQ:SNYR

$3.63 +0.20 (+5.83%)

As of 07/17/2025 04:00 PM Eastern

Synergy CHC Corp. engages in the marketing and distribution of branded health and wellness products. The company was founded on December 29, 2010 and is headquartered in Westbrook, ME.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time